Blackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V (“BXLS V”), the inaugural Blackstone fund in Life Sciences. BXLS V was oversubscribed and closed at its hard cap of $4.6 billion of total capital commitments — the largest life sciences private fund raised to date.
Hudson Pacific Properties, Inc. (“Hudson Pacific”) (NYSE: HPP) and Blackstone (NYSE: BX) today announced that funds affiliated with Blackstone Property Partners will acquire a 49% interest in Hudson Pacific’s three Hollywood studios and five on-lot or adjacent Class A office properties, totaling 2.2 million square feet, at a gross portfolio valuation of $1.65 billion.
Medtronic plc (NYSE:MDT) and Blackstone (NYSE:BX) today announced that Medtronic intends to significantly increase research and development (R&D) funding in its Diabetes Group through an agreement to receive $337 million of funding from funds managed by Blackstone Life Sciences (“BXLS”) including co-investors, aimed at advancing new, innovative products especially designed to reduce the burden of diabetes management.
Blackstone (NYSE: BX) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata”), a clinical-stage biopharmaceutical company, today announced that funds managed by Blackstone Life Sciences (“BXLS”) will lead a $350 million royalty and equity investment in Reata to fund the development and potential commercialization of bardoxolone methyl (“bardoxolone”), an investigational once-daily oral therapy being studied for chronic kidney disease (“CKD”) in Alport syndrome, autosomal dominant polycystic kidney disease (“ADPKD”), and other associated potential future indications.
Blackstone Singapore announced today a donation of nearly $600,000 to Community Chest, the fundraising and engagement arm of the National Council of Social Service. The contribution will provide assistance for vulnerable members of the community impacted by the COVID-19 outbreak and includes funding from Blackstone Singapore, its employees and the Blackstone Charitable Foundation.
Blackstone (NYSE:BX) today announced the appointment of Dr. Mark McClellan (MD, PhD), a physician and economist who served as both the commissioner of the U.S. Food and Drug Administration (FDA) and administrator of the Centers for Medicare & Medicaid Services (CMS), as a Senior Advisor.
Blackstone (NYSE:BX) announced today that Jon Gray, President & Chief Operating Officer, is scheduled to present at the Morgan Stanley Virtual US Financials Conference on Wednesday, June 10, 2020 at 12:00 pm ET.
Blackstone (NYSE: BX) announced today that Stephen Schwarzman, Chairman, CEO and Co-Founder, is scheduled to present virtually at Bernstein’s 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 1:30PM ET.
Blackstone (NYSE: BX) announced that Vini Letteri will join Blackstone Growth (“BXG”), the firm’s recently launched global growth equity investing platform. He will be a Senior Managing Director and brings two decades of experience as a seasoned growth equity investor and operations professional.
Blackstone and Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the companies have entered into a broad strategic collaboration under which Blackstone will provide up to $2 billion to support Alnylam’s advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases.
New York – April 9, 2020, Blackstone (NYSE:BX) announced today that funds managed by Blackstone ("Blackstone") have completed their previously announced acquisition of a majority stake in HealthEdge Software (“HealthEdge”), a leading healthcare technology company that delivers next generation Core Administrative Processing Systems (CAPS) solutions to customers across the healthcare ecosystem.